MA55804A - Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2 - Google Patents

Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2

Info

Publication number
MA55804A
MA55804A MA055804A MA55804A MA55804A MA 55804 A MA55804 A MA 55804A MA 055804 A MA055804 A MA 055804A MA 55804 A MA55804 A MA 55804A MA 55804 A MA55804 A MA 55804A
Authority
MA
Morocco
Prior art keywords
mrgx2
thiadiazine
benzo
inhibitors
amino
Prior art date
Application number
MA055804A
Other languages
English (en)
Inventor
Simone Bigi
Allison L Chambers
Tony Gibson
Mitsunori Kono
Jason Pickens
Masaki Seto
Zenyu Shiokawa
Steve Swann
Angie Vassar
Feng Zhou
Original Assignee
Solent Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solent Therapeutics Llc filed Critical Solent Therapeutics Llc
Publication of MA55804A publication Critical patent/MA55804A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055804A 2019-04-29 2020-04-28 Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2 MA55804A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962840344P 2019-04-29 2019-04-29

Publications (1)

Publication Number Publication Date
MA55804A true MA55804A (fr) 2022-04-06

Family

ID=70779887

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055804A MA55804A (fr) 2019-04-29 2020-04-28 Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2

Country Status (21)

Country Link
US (2) US12247015B2 (fr)
EP (1) EP3962901A1 (fr)
JP (1) JP7574215B2 (fr)
CN (2) CN120535477A (fr)
AR (1) AR119728A1 (fr)
AU (1) AU2020266529B2 (fr)
BR (1) BR112021021508A2 (fr)
CL (1) CL2021002805A1 (fr)
CO (1) CO2021014155A2 (fr)
CR (1) CR20210544A (fr)
DO (1) DOP2021000223A (fr)
EC (1) ECSP21080966A (fr)
IL (1) IL287521B2 (fr)
JO (1) JOP20210275A1 (fr)
MA (1) MA55804A (fr)
MX (1) MX2021013135A (fr)
PE (1) PE20220425A1 (fr)
PH (1) PH12021552760A1 (fr)
SG (1) SG11202111717XA (fr)
TW (1) TWI846868B (fr)
WO (1) WO2020223255A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120535477A (zh) 2019-04-29 2025-08-26 索伦特治疗有限责任公司 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
WO2022152852A1 (fr) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonistes de mrgx2
WO2022152853A1 (fr) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonistes de mrgx2
WO2024183806A1 (fr) * 2023-03-08 2024-09-12 InventisBio Co., Ltd. Composés, leurs procédés de préparation et leurs utilisations
WO2025037034A1 (fr) * 2023-08-17 2025-02-20 Sanofi Thiénothiadiazines, leur préparation et leur application thérapeutique
TW202515858A (zh) 2023-08-18 2025-04-16 美商英塞特公司 作為ｍｒｇｐｒｘ２拮抗劑之雙環雜環化合物
TW202517273A (zh) * 2023-10-06 2025-05-01 美商伊賽恩特製藥公司 Ｍｒｇｐｒｘ２調節劑及相關治療方法
CN120230034A (zh) * 2023-12-29 2025-07-01 深圳阿尔法分子科技有限责任公司 喹诺酮类化合物及其用途
WO2025160430A1 (fr) 2024-01-25 2025-07-31 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'antagonistes de mrgprx2
WO2025222040A1 (fr) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Modulateurs de mrgprx2 destinés à être utilisés dans le traitement d'affections dépendantes de mrgprx2 chez des sujets à faible taux d'ige
WO2026009854A1 (fr) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 Composé de pyridazine et son utilisation pharmaceutique

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757999A1 (de) * 1977-12-24 1979-06-28 Bayer Ag Substituierte aminoalkylenamino- 1.2.4-benzothiadiazine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0105732A3 (fr) 1982-10-01 1985-09-04 Beecham Group Plc Antagonistes de récepteurs d'histamine H2 des séries benzisothiazole amino et benzothiadiazine amino
EP0386931A1 (fr) 1989-03-04 1990-09-12 Konica Corporation Coupleur de colorant bleu-vert
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6242443B1 (en) 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999032467A1 (fr) 1997-12-19 1999-07-01 Novo Nordisk A/S Derives de 1,2,4-benzothiadiazine, leur preparation et leur utilisation
CA2320354A1 (fr) 1998-02-18 1999-08-26 Neurosearch A/S Nouveaux composes et leur utilisation comme modulateurs positifs du recepteur ampa
WO2003004604A2 (fr) 2001-07-06 2003-01-16 Genentech, Inc. Ligands du domaine pdz exprimes a la surface des phages
EP1340979A3 (fr) 2002-02-27 2004-02-04 Pfizer Limited Récepteur neuropeptidique et son utilisation
US7517875B2 (en) 2002-04-16 2009-04-14 Teijin Limited Piperidine derivatives having CCR3 antagonism
CN100360521C (zh) 2002-04-25 2008-01-09 帝人株式会社 具有ccr3拮抗作用的4,4-二取代的哌啶衍生物
AU2003238287A1 (en) 2002-06-21 2004-01-06 California Institute Of Technology Identification of a receptor controlling migration and metastasis of skin cancer cells
WO2005019191A2 (fr) 2003-08-25 2005-03-03 Abbott Laboratories Agents anti-infectieux
WO2005028667A1 (fr) 2003-09-19 2005-03-31 Riken Recepteur couple a la proteine g pour le ciblage de medicament exprime dans des mastocytes humains et procede de criblage de ce recepteur
CN1909909B (zh) 2004-01-16 2010-12-15 弗·哈夫曼-拉罗切有限公司 作为5-羟色胺受体(5-ht)调节剂用于治疗中枢神经系统疾病的1-苄基-5-哌嗪-1-基-3，4二氢-1h-喹唑啉-2-酮衍生物和各个1h-苯并(1，2，6)噻二嗪-2，2-二氧化物和1，4-二氢-苯并(d)(1，3)*嗪-2-酮衍生物
JP2008515783A (ja) 2004-09-15 2008-05-15 プロトメトリックス インコーポレイティッド タンパク質アレイ及びその使用方法
WO2006062316A1 (fr) 2004-12-08 2006-06-15 Electronics And Telecommunications Research Institute Procede permettant de regler des stations de base de maniere a supprimer les interferences intercellulaires
WO2006089286A2 (fr) * 2005-02-18 2006-08-24 Acadia Pharmaceuticals Inc. Composes utiles pour traiter et prevenir la douleur et procedes de criblage associes
US20090214477A1 (en) 2005-04-15 2009-08-27 Cenix Bioscience Gmbh Human Marker Genes and Agents for Diagnosis, Treatment and Prophylaxis of Cardiovascular Disorders and Artherosclerosis
WO2006118328A1 (fr) 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited Inhibiteur de degranulation
EP1893627A4 (fr) 2005-05-27 2009-11-11 Sentigen Biosciences Inc Reseau multiplex utile pour le dosage d'interaction proteine-proteine
WO2007053514A2 (fr) 2005-10-31 2007-05-10 University Of Rochester Preconditionnement chimique pour la prevention ou le traitement de degats synaptiques excitotoxiques
JP2009060787A (ja) 2005-11-15 2009-03-26 Gunma Univ Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
WO2008043561A2 (fr) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cibles de la grippe
US20080249081A1 (en) * 2006-10-24 2008-10-09 Roger Olsson Compounds for the treatment of pain and screening methods therefor
WO2008061209A2 (fr) 2006-11-15 2008-05-22 Omeros Corporation Récepteurs couplés à la protéine g et leurs utilisations
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
EP2067861A1 (fr) 2007-12-05 2009-06-10 Koninklijke Nederlandse Akademie van Wetenschappen Animaux de l'espèce rattus pour lesquels l'expression msh6 est diminuée fonctionnellement et procédés pour la génération de mutants spécifiques à partir de ceux-ci
JP2012167017A (ja) 2009-06-15 2012-09-06 National Cerebral & Cardiovascular Center ペプチドおよびその用途
EP3211094A3 (fr) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Procédés pour traiter, diagnostiquer, et surveiller la polyarthrite rhumatoïde
IT1402905B1 (it) * 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
JP5932279B2 (ja) 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
WO2013130411A1 (fr) 2012-02-27 2013-09-06 Essentialis, Inc. Sels d'ouvreurs des canaux potassiques atp et leurs utilisations
AU2013326867B2 (en) 2012-10-05 2018-03-08 Rigel Pharmaceuticals, Inc. GDF-8 inhibitors
US20160096874A1 (en) 2013-06-18 2016-04-07 Bayer Pharma Aktiengesellschaft Mrg receptor modulators
WO2015117024A1 (fr) 2014-01-31 2015-08-06 Mayo Foundation For Medical Education And Research Nouveaux agents thérapeutiques pour le traitement du glaucome
WO2015157093A1 (fr) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. Composés de pyridine 2,3-disubstitués utilisés comme inhibiteurs de tgf-bêta et procédés d'utilisation
WO2016118632A1 (fr) 2015-01-20 2016-07-28 The General Hospital Corporation Prévention et traitement de prurit avec un antagoniste de mrgpr
EP3383493B1 (fr) 2015-12-04 2021-02-17 Merck Sharp & Dohme Corp. Dioxydes d'iminothiadiazine carbocycliques condensés utilisés comme inhibiteurs de bace, compositions, et utilisation associée
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
CA3057261A1 (fr) 2017-04-06 2018-10-11 Inventiva Nouveaux composes inhibiteurs de l'interaction yap/taz-tead et leur utilisation dans le traitement du mesotheliome malin
WO2018213934A1 (fr) 2017-05-26 2018-11-29 The Governors Of The University Of Alberta Peptide auto-assemblé servant à activer des mastocytes humains
SI3814348T1 (sl) 2018-06-27 2023-10-30 Bristol-Myers Squibb Company Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic
EP3597653A1 (fr) 2018-07-19 2020-01-22 Irbm S.P.A. Inhibiteurs cycliques du virus de l'hépatite b
CN120535477A (zh) 2019-04-29 2025-08-26 索伦特治疗有限责任公司 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物

Also Published As

Publication number Publication date
BR112021021508A2 (pt) 2022-03-22
IL287521A (en) 2021-12-01
CL2021002805A1 (es) 2022-07-22
TW202106669A (zh) 2021-02-16
AU2020266529B2 (en) 2026-01-29
IL287521B1 (en) 2025-09-01
US20250289792A1 (en) 2025-09-18
CR20210544A (es) 2022-03-30
AU2020266529A1 (en) 2021-12-16
SG11202111717XA (en) 2021-11-29
CN114072393A (zh) 2022-02-18
DOP2021000223A (es) 2022-01-16
KR20220012244A (ko) 2022-02-03
JP7574215B2 (ja) 2024-10-28
MX2021013135A (es) 2021-11-25
JOP20210275A1 (ar) 2023-01-30
PH12021552760A1 (en) 2022-08-15
PE20220425A1 (es) 2022-03-29
WO2020223255A1 (fr) 2020-11-05
ECSP21080966A (es) 2022-01-31
EP3962901A1 (fr) 2022-03-09
TWI846868B (zh) 2024-07-01
US20220119361A1 (en) 2022-04-21
JP2022535672A (ja) 2022-08-10
US12247015B2 (en) 2025-03-11
CN114072393B (zh) 2025-05-27
AR119728A1 (es) 2022-01-05
IL287521B2 (en) 2026-01-01
CN120535477A (zh) 2025-08-26
CA3137584A1 (fr) 2020-11-05
CO2021014155A2 (es) 2021-10-29

Similar Documents

Publication Publication Date Title
MA55804A (fr) Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
EP3784665A4 (fr) Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
EP3941525A4 (fr) Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
EP4077312A4 (fr) Dérivés spiro à chaîne droite substitués
MA54157A (fr) Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3849541A4 (fr) Dérivés de 2,3-dihydrobenzo[b]thiophène en tant qu'inhibiteurs du facteur 2(alpha) inductible par l'hypoxie
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
EP4043450A4 (fr) Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP4073033A4 (fr) Dérivés cannabinoïdes
MA51133A (fr) Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc
EP4037676A4 (fr) Dérivés cannabinoïdes
EP3997095A4 (fr) Dérivés cannabinoïdes